With ri­val to an­ti-TNF in­jecta­bles, Pro­tal­ix re­ports pos­i­tive PhII da­ta in ul­cer­a­tive col­i­tis

An Is­raeli biotech look­ing to make a pill that would re­place an­ti-TNF in­jecta­bles — a multi­bil­lion dol­lar mar­ket — to­day re­port­ed good news from its small Phase …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.